Flagship record · Retatrutide

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.

reviewnarrative reviewclass level evidence

Scientific attribution

The review addresses GLP-1 medicines and newer metabolic agents at a class level rather than retatrutide-specific primary evidence.

PMID: 38843460
DOI: 10.2337/dci24-0003
Sample size: Not captured in the structured review record
Population / model: The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations.

Key findings

Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders.

Review status

This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.

Loading research intelligence

Preparing the structured Flagship evidence library.